You recently learned that your child has Crohn’s disease or ulcerative colitis. Now you’re taking an important step: learning about these conditions, how they’re treated, and how your child can learn to live with IBD.
The Crohn's & Colitis Foundation's purpose is to start you on an educational path—to inform you of some key points about Crohn’s disease and ulcerative colitis, and what you may expect. You won’t become an expert overnight, but gradually you’ll learn more. And the more you know, the better you’ll be able to become an advocate for your child. Most important: You’ll be an active member of your child’s healthcare team.
Podcast Series for IBD Patients and Families - Maintaining Healthy Nutrition in Pediatric IBD Patients
Resources for Parents
- Parent's IBD Brochure
- Living with Crohn's Disease
- Living with ulcerative colitis
- Discussion guide for parents
- Healthcare Maintenance Discussion Guide
- IBD Medication Guide
- Brochure for Teachers and other school personnel
- Find a doctor
- Talk to an Information Specialist
- Join an online community
- Find a support group
Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis. Below you’ll find our most recent press releases, along with other articles written by the Crohn's & Colitis Foundation.
This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources.
Thank you to the Allergan Foundation for investing in Camp Oasis with a $5,000 grant! From Left to right: Bill Meury, Allergan Foundation board member and Executive VP, Chief Commercial Officer; Jonathon Kellerman, Allergan Foundation board member and Executive VP, Global Chief Compliance Officer; Denise Desmond, Crohn’s & Colitis Foundation Orange County Chapter, Executive Director, Gwyn Grenrock, Executive Director of The Allergan Foundation; and Alex Kelly, Allergan Foundation President and Executive VP, Chief Communications Officer.
Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives FundingMay 17, 2018
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.
Clinical trial recruitment is the biggest barrier to the development and approval of new treatments. In order to understand patient perceptions and improve recruitment, the Crohn’s & Colitis Foundation conducted in-person focus groups over a four-month period in 2016, the results of which are published in the paper "Crohn’s disease and ulcerative colitis patient perspectives on clinical trials and participation."
Leading Patient & Professional Organizations Announce Funding to Improve Communications & Address Shared Decision-making in Inflammatory Bowel DiseasesApril 17, 2018
The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
The Crohn's & Colitis Foundation Selects Diversigen, Inc. as a Preferred Provider for Metagenomics and Microbiome Analysis ServicesApril 11, 2018
Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform.
exploring the relationship between accutane and ulcerative colitis